Skip to main content
Top
Published in: Journal of Hematology & Oncology 1/2015

Open Access 01-12-2015 | Letter to the Editor

Platelet functional alterations in a Bernard-Soulier syndrome patient with filamin A mutation

Authors: Jiaming Li, KeSheng Dai, Zhaoyue Wang, Lijuan Cao, Xia Bai, Changgeng Ruan

Published in: Journal of Hematology & Oncology | Issue 1/2015

Login to get access

Abstract

Defects in filamin A (FLNA) gene could lead to low platelet counts and decreased surface expression of glycoprotein (GP) Ibα. Here, we report and investigate the FLNA genomic alteration of a case with Bernard-Soulier syndrome (BSS), a rare hereditary bleeding disorder caused by quantitative or qualitative abnormalities in the GP Ib-IX-V receptor. DNA sequencing analysis reveals the presence of a GP Ibα c.987G > A mutation and a FLNA c.1582 G > A mutation in this patient. Transient transfection studies show that GP Ibα c.987G > A mutation abolishes the surface expression of GP Ibα on the transfected CHO cells. On the other hand, abnormal responses to collagen, including the platelet aggregation, secretion, and GP VI signaling pathways, are associated with FLNA c.1582G > A mutation. Our findings confirm a central role for FLNA in platelet-adhesive functions. The interaction between FLNA and GP Ibα in platelets deserves to be investigated.
Literature
1.
go back to reference Williamson D, Pikovski I, Cranmer SL, Mangin P, Mistry N, Domagala T, et al. Interaction between platelet glycoprotein Ibα and filamin-1 is essential for glycoprotein Ib/IX receptor anchorage at high shear. J Biol Chem. 2002;277:2151–9.PubMedCrossRef Williamson D, Pikovski I, Cranmer SL, Mangin P, Mistry N, Domagala T, et al. Interaction between platelet glycoprotein Ibα and filamin-1 is essential for glycoprotein Ib/IX receptor anchorage at high shear. J Biol Chem. 2002;277:2151–9.PubMedCrossRef
2.
go back to reference Nurden P, Debili N, Coupry I, Bryckaert M, Youlyouz-Marfak I, Solé G, et al. Thrombocytopenia resulting from mutations in filamin A can be expressed as an isolated syndrome. Blood. 2011;118:5928–37.PubMedCrossRef Nurden P, Debili N, Coupry I, Bryckaert M, Youlyouz-Marfak I, Solé G, et al. Thrombocytopenia resulting from mutations in filamin A can be expressed as an isolated syndrome. Blood. 2011;118:5928–37.PubMedCrossRef
3.
go back to reference Ichinohe T, Takayama H, Ezumi Y, Arai M, Yamamoto N, Takahashi H, et al. Collagen-stimulated activation of Syk but not c-Src is severely compromised in human platelets lacking membrane glycoprotein VI. J Biol Chem. 1997;272:63–8.PubMedCrossRef Ichinohe T, Takayama H, Ezumi Y, Arai M, Yamamoto N, Takahashi H, et al. Collagen-stimulated activation of Syk but not c-Src is severely compromised in human platelets lacking membrane glycoprotein VI. J Biol Chem. 1997;272:63–8.PubMedCrossRef
4.
go back to reference Falet H, Pollitt AY, Begonja AJ, Weber SE, Duerschmied D, Wagner DD, et al. A novel interaction between FLNA and Syk regulates platelet ITAM-mediated receptor signaling and function. J Exp Med. 2010;207:1967–79.PubMedCentralPubMedCrossRef Falet H, Pollitt AY, Begonja AJ, Weber SE, Duerschmied D, Wagner DD, et al. A novel interaction between FLNA and Syk regulates platelet ITAM-mediated receptor signaling and function. J Exp Med. 2010;207:1967–79.PubMedCentralPubMedCrossRef
Metadata
Title
Platelet functional alterations in a Bernard-Soulier syndrome patient with filamin A mutation
Authors
Jiaming Li
KeSheng Dai
Zhaoyue Wang
Lijuan Cao
Xia Bai
Changgeng Ruan
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2015
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-015-0171-z

Other articles of this Issue 1/2015

Journal of Hematology & Oncology 1/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine